– USA, TX – Socrates Health Solutions, Inc., which is developing the Socrates CompanionTM, a pain-free, accurate and affordable noninvasive blood glucose monitoring device, announces the appointment of Douglas Sutherland to its Board of Directors. An active investor in diabetes-related start-up companies, Sutherland has held senior leadership positions at high-profile global companies and is currently serving as the Non-executive Chairman of Regus plc, the world’s largest provider of workspaces. Previously, Sutherland was the chief financial officer of Skype during its acquisition by Ebay, was a partner at Arthur Andersen with global management responsibilities, was the chief financial officer of SecureWave during its acquisition by Patchlink, was a director of Median Kliniken GmbH, Germany’s largest private sector chain of health rehabilitation clinics, during its recent sale to Waterline Private Equity Investments BV, and was the founding Chairman of the American Chamber of Commerce in Luxembourg.
“Douglas brings vast experience and expertise with some of the world’s most successful organizations, and will be instrumental in advancing our mission to improve the lives of diabetics by providing an affordable noninvasive blood glucose self-monitoring device,” says Scott Smith, CEO, Socrates. “With his expertise in leading and building world-class growth companies, Douglas will play a key role in our initiatives to better serve the growing diabetic population worldwide.”
Sutherland adds, “The Socrates Companion, a sensor that is attached to the ear, generates an accurate blood glucose reading in seconds. It is gratifying to join the team that is advancing the positioning and adoption of this device which offers compelling healthcare, lifestyle and cost benefits to consumers and their caregivers, and will help millions of people to access a simpler, less costly way to test their blood glucose levels.”
About Socrates Health Solutions, Inc.
Socrates Health is developing Socrates CompanionTM, a small, inexpensive and noninvasive blood glucose self-monitoring device that has not yet been cleared by the FDA and is currently not for sale.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.